Luminal A and B breast cancers, characterized by positivity for estrogen receptor (ER), are the most heterogeneous ones, but are well responsive to hormone therapy, while patients carrying the HER2 subtype of breast cancer are sensitive to trastuzumab treatment [5]. Here, ESR1 is linked to breast carcinoma.